The FDA approved Regeneron and Sanofi’s Dupixent for atopic dermatitis, a product widely seen as the most important future growth driver for the companies.

Investors and biotech insiders are waiting during March 2017 for the U.S. Food and Drug Administration to rule on six therapies that will impact the bottom line of the developers, according to an analysis by RTT News.

A Pfizer Inc. ointment to treat mild to moderate cases of the itchy skin condition eczema, or atopic dermatitis, won U.S. approval for use in patients aged 2 years and older, the Food and Drug Administration said.

The European Medicines Agency (EMA) – the European Union’s health regulator – has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron.

An atopic dermatitis treatment in Phase III development by Regeneron Pharmaceuticals and Sanofi met primary endpoints in two placebo-controlled trials.

Allergan plc will acquire Vitae Pharmaceuticals Inc. for $21.00 per share, in cash, for a total transaction value of approximately $639 million.

British drugmaker AstraZeneca Plc said it sold the rights to develop an experimental mid-stage drug to treat atopic dermatitis to privately-held LEO Pharma.

In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread […]

July 13, 2015By Mark Terry, BioSpace.com Breaking News Staff Palo Alto, Calif.-based Anacor Pharmaceuticals, Inc. (ANAC) announced positive results today from two Phase III clinical trials of Crisaborole Topical Ointment […]